Table 4.
Some of ongoing clinical studies of nucleic acid therapeutics for cancer treatment
| NCT number | Drugs | Delivery System | Indications | Sponsor | Phase |
|---|---|---|---|---|---|
| NCT01591356 | EphA2 siRNA | Neutral liposome | Advanced malignant solid neoplasm | M.D. Anderson Cancer Center | Phase 1 |
| NCT03819387 | NBF-006 | LNP | Non-small cell lung, pancreatic, or colorectal cancer | Nitto BioPharma, Inc | Phase 1 |
| NCT04196257 | BP1001-A | Liposome | Advanced or recurrent solid tumors | Bio-Path Holdings, Inc | Phase 1 |
| NCT05267899 | WGI-0301 | LNP | Advanced hepatocellular carcinoma | Zhejiang Haichang Biotech Co., Ltd | Phase 2 |
| NCT05969041 | MT-302 (A) | LNP | Advanced/Metastatic epithelial tumors | Myeloid therapeutics | Phase 1 |
| NCT05497453 | OTX-2002 | LNP | Hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene | Omega Therapeutics | Phase 1 and 2 |
| NCT06389591 | RNA-LP vaccine | Lipid particles | Recurrent glioblastoma | University of Florida | Phase 1 |
| NCT04573140 | RNA-LP vaccine | Lipid particles | Newly diagnosed pediatric high-grade gliomas and adult glioblastoma | University of Florida | Phase 1 |
| NCT05660408 | RNA-LP vaccine | Lipid particles | Pulmonary osteosarcoma | University of Florida | Phase 1 and 2 |
| NCT03608631 | KRAS G12D siRNA | Exosome | Metastatic pancreatic adenocarcinoma | M.D. Anderson Cancer Center | Phase 1 |